Treatment of toxoplasmosis with trimethoprim-sulphamethoxazole.
Toxoplasmosis is known to complicate diseases with impaired cellular immunity. For treatment of toxoplasma infections atoxic drugs should be used to avoid depression of the bone marrow. The hitherto recommended treatment, pyrimethamine in combination with sulphonamides, is often associated with severe side-effects. The present study presents the results of treatment with trimethoprim and sulphamethoxazole in 7 patients, clinically and serologically diagnosed as having toxoplasmosis. Good therapeutic results were observed in 5 patients with lymphoglandular toxoplasmosis and a significant reduction of the dye test titres were found in 6 patients. In one patient, however, a relapse of clinical symptoms and a reversion to high dye test titres were observed 6 1/2 months after the end of the treatment. Treatment had to be discontinued in one patient due to an allergic reaction.
D000293:Adolescent; D000328:Adult; D002675:Child, Preschool; D002825:Chorioretinitis / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D013280:Stomatitis / Q000139:chemically induced; D013420:Sulfamethoxazole / Q000009:adverse effects / Q000627:therapeutic use*; D014123:Toxoplasmosis / Q000188:drug therapy*; D014295:Trimethoprim / Q000009:adverse effects / Q000627:therapeutic use*
D014295:Trimethoprim; D013420:Sulfamethoxazole